Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.59 |
| ▸ | F2 | P00734 | 4/20 | 0.59 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 3/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16948138 | 0.90 | F10 (0.64) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL15731769 | 0.89 | F10 (0.67) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL5307046 | 0.89 | F10 (0.67) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL2000886 | 0.89 | F10 (0.63) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL1995178 | 0.88 | F10 (0.62) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL18660272 | 0.88 | F10 (0.62) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL14348232 | 0.88 | F10 (0.78) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL18040316 | 0.87 | F10 (0.61) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL18040318 | 0.87 | F10 (0.61) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL18058755 | 0.87 | F10 (0.61) | F10F2SLC29A1PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122557-B2 | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-17 | — | — | US | disclosed |
| US-20040209863-A1 | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209863-A1 | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors | TFPI, SPINT2, TMPRSS4 | F10 37/4885F2 15/4885SLC29A1 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.